Cabotegravir plus rilpivirine - Janssen Therapeutics/ViiV Healthcare

Drug Profile

Cabotegravir plus rilpivirine - Janssen Therapeutics/ViiV Healthcare

Alternative Names: CAB LA + RPV LA combination therapy; Cabotegravir plus rilpivirine combination therapy; GSK 1265744 plus rilpivirine combination therapy; GSK 1265744 plus TMC 278 combination therapy; Long-acting cabotegravir plus long-acting rilpivirine combination therapy

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator Janssen Pharmaceuticals; ViiV Healthcare
  • Developer GlaxoSmithKline; Janssen Pharmaceuticals; ViiV Healthcare
  • Class Fluorobenzenes; Nitriles; Oxazoles; Pyrazines; Pyridones; Pyrimidines; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV infections

Most Recent Events

  • 12 Dec 2016 Chemical structure information added
  • 09 Dec 2016 No development reported - Phase-I for HIV infections (Combination therapy, In volunteers) in USA (SC)
  • 01 Oct 2016 Phase-III clinical trials in HIV infections (Combination therapy, Treatment-naive) in Netherlands (IM) (EudraCT2016-001646-25)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top